USD 0.88
(-5.44%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 1.13 Million USD | -74.07% |
2022 | 6.26 Million USD | -5.54% |
2021 | 6.63 Million USD | 7.09% |
2020 | 6.19 Million USD | -45.35% |
2019 | 11.33 Million USD | 20.37% |
2018 | 9.41 Million USD | 0.0% |
2017 | - USD | -100.0% |
2016 | 2.56 Million USD | -60.14% |
2015 | 6.42 Million USD | -33.83% |
2014 | 9.7 Million USD | 93.72% |
2013 | 5.01 Million USD | 0.0% |
2012 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 1.5 Million USD | -7.14% |
2024 Q2 | 1.38 Million USD | -7.92% |
2023 FY | 1.62 Million USD | -74.07% |
2023 Q3 | 1.73 Million USD | 27.62% |
2023 Q2 | 1.36 Million USD | -82.03% |
2023 Q1 | 7.57 Million USD | 20.83% |
2023 Q4 | 1.62 Million USD | -6.45% |
2022 Q3 | 6.36 Million USD | -1.46% |
2022 Q1 | 6.54 Million USD | -1.3% |
2022 Q4 | 6.26 Million USD | -1.53% |
2022 FY | 6.26 Million USD | -5.54% |
2022 Q2 | 6.45 Million USD | -1.38% |
2021 Q1 | 6.12 Million USD | 6.37% |
2021 FY | 6.63 Million USD | 7.09% |
2021 Q2 | 6.69 Million USD | 9.26% |
2021 Q3 | 6.71 Million USD | 0.3% |
2021 Q4 | 6.63 Million USD | -1.23% |
2020 Q2 | 10.92 Million USD | -0.09% |
2020 Q4 | 5.76 Million USD | -1.79% |
2020 FY | 6.19 Million USD | -45.35% |
2020 Q1 | 10.93 Million USD | -0.07% |
2020 Q3 | 5.86 Million USD | -46.32% |
2019 Q2 | 10.95 Million USD | -0.01% |
2019 FY | 11.33 Million USD | 20.37% |
2019 Q4 | 10.94 Million USD | -0.03% |
2019 Q3 | 10.95 Million USD | -0.01% |
2019 Q1 | 10.95 Million USD | 16.31% |
2018 Q2 | 9.22 Million USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 FY | 9.41 Million USD | 0.0% |
2018 Q4 | 9.41 Million USD | 1.05% |
2018 Q3 | 9.31 Million USD | 1.06% |
2017 Q2 | - USD | -100.0% |
2017 FY | - USD | -100.0% |
2017 Q4 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q1 | 1.47 Million USD | -42.52% |
2016 Q3 | 3.59 Million USD | -21.52% |
2016 Q2 | 4.57 Million USD | -17.06% |
2016 Q1 | 5.52 Million USD | -14.06% |
2016 FY | 2.56 Million USD | -60.14% |
2016 Q4 | 2.56 Million USD | -28.74% |
2015 Q4 | 6.42 Million USD | -12.26% |
2015 Q3 | 7.32 Million USD | -10.19% |
2015 Q2 | 8.15 Million USD | -8.86% |
2015 Q1 | 8.94 Million USD | -7.86% |
2015 FY | 6.42 Million USD | -33.83% |
2014 Q4 | 9.7 Million USD | 1.24% |
2014 Q3 | 9.58 Million USD | -0.58% |
2014 Q2 | 9.64 Million USD | 92.9% |
2014 Q1 | 5 Million USD | -0.22% |
2014 FY | 9.7 Million USD | 93.72% |
2013 Q1 | 5 Million USD | 0.0% |
2013 FY | 5.01 Million USD | 0.0% |
2013 Q3 | 4.26 Million USD | -9.46% |
2013 Q2 | 4.71 Million USD | -5.8% |
2013 Q4 | 5.01 Million USD | 17.49% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | 96.882% |
Dynavax Technologies Corporation | 256.91 Million USD | 99.557% |
Cara Therapeutics, Inc. | 43.16 Million USD | 97.361% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.988% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 97.257% |
Perrigo Company plc | 4.07 Billion USD | 99.972% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | 98.031% |
Illumina, Inc. | 2.26 Billion USD | 99.95% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.997% |
Nektar Therapeutics | 230.4 Million USD | 99.506% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -13.929% |
IQVIA Holdings Inc. | 14.23 Billion USD | 99.992% |
Heron Therapeutics, Inc. | 173.75 Million USD | 99.344% |
Unity Biotechnology, Inc. | 26.99 Million USD | 95.779% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.9% |
Waters Corporation | 2.35 Billion USD | 99.952% |
Biogen Inc. | 7.33 Billion USD | 99.984% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | 97.01% |
Adicet Bio, Inc. | 17.7 Million USD | 93.564% |
Agilent Technologies, Inc. | 2.73 Billion USD | 99.958% |
Homology Medicines, Inc. | 44.05 Million USD | 97.414% |
Geron Corporation | 85.89 Million USD | 98.674% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.952% |
Amicus Therapeutics, Inc. | 445.05 Million USD | 99.744% |
Myriad Genetics, Inc. | 145 Million USD | 99.214% |
Evolus, Inc. | 126.54 Million USD | 99.1% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
bluebird bio, Inc. | 330.32 Million USD | 99.655% |
Intellia Therapeutics, Inc. | 115.34 Million USD | 99.012% |
Zoetis Inc. | 6.8 Billion USD | 99.983% |
Abeona Therapeutics Inc. | 4.4 Million USD | 74.119% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | 62.938% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 99.947% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.859% |
uniQure N.V. | 138.4 Million USD | 99.177% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | 96.863% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.922% |
Verastem, Inc. | 41.55 Million USD | 97.258% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 99.789% |
FibroGen, Inc. | 170.45 Million USD | 99.332% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.918% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 94.545% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.734% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.958% |
OPKO Health, Inc. | 326.56 Million USD | 99.651% |
Viking Therapeutics, Inc. | 1.26 Million USD | 9.58% |
Exelixis, Inc. | 189.94 Million USD | 99.4% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.924% |
Axsome Therapeutics, Inc. | 186.37 Million USD | 99.389% |
Blueprint Medicines Corporation | 774.12 Million USD | 99.853% |
Insmed Incorporated | 1.2 Billion USD | 99.905% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | 98.001% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -654.499% |
TG Therapeutics, Inc. | 110.79 Million USD | 98.972% |
Incyte Corporation | 38.28 Million USD | 97.024% |
Emergent BioSolutions Inc. | 877.5 Million USD | 99.87% |